From Monkeys To Men: Panel Will Review Use Of Animal Rule For Filgrastim As Radiation Countermeasure
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Medical Imaging Drugs and Oncologic Drugs Advisory Committee will discuss whether evidence supports approval of filgrastim as a medical countermeasure for radiation-induced bone marrow injury using the “animal rule.”